• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Cancer Core Europe consortium launches

Cancer Core Europe consortium launches

September 26, 2014
CenterWatch Staff

Cancer Core Europe—a consortium to address the cancer care/research continuum challenge, has launched. Its members are Gustave Roussy Cancer Campus Grand Paris; Cambridge Cancer Center, based in the U.K.; Karolinska Institute, of Stockholm, Sweden; the Netherlands Cancer Institute; Vall d'Hebron Institute of Oncology (VHIO), of Barcelona, Spain; and the German Cancer Research Center (DKFZ) and its National Center for Tumor Diseases (NCT).

The optimal treatment of cancer remains one of the major medical challenges globally due to the high diversity in the spectrum of mutations in individual cancer patients. To tackle this issue, cancer programs must be better integrated and performed at a large scale. European cancer research is therefore in need of a transformative initiative whereby a consortium of comprehensive cancer centers of excellence will work collectively in order to carry out joint translational and clinical research in cancer treatment and care.

As a working consortium, Cancer Core Europe will be a translational platform to make the bridge "bench-to-bedside and bedside-to-bench" also for conducting next-generation clinical trials focused on proof-of-concept, companion predictive and resistance monitoring biomarkers.

The prerequisites for joint translational and clinical research programs are very demanding. They require a powerful translational platform that integrates all patient files using a common software platform that federates the databases from each of the centers; inter-compatible clinical molecular profiling laboratories with a robust underlying computational biology pipeline; standardized functional and molecular imaging; commonly agreed SOPs for liquid and tissue biopsy procurement, storage and processing, for molecular diagnostics, "omics," functional genetics and immune-monitoring; a culture of data collection; and storage that facilitates complete longitudinal data sets.

Cancer Core Europe will be able to support the full spectrum of research required to address the cancer research/care continuum. Cancer Core Europe also constitutes a unique environment for the training of up-and-coming talents in innovative translational and clinical oncology.

Yearly, within the Cancer Core Europe consortium, around 60,000 newly diagnosed cancer patients are seen, 300,000 cancer treatments are delivered and about one million outpatient visits are performed. More than 1,500 clinical trials are being conducted at these six cancer centers annually. Together with the strengths in basic and translational cancer research, this represents a unique critical mass of activity that once successfully harmonized as one operational clinical research structure will represent and harness a major force in European cancer research.

“Our understanding of cancer is increasing faster than ever before, and over the next decade or so I believe that this will lead to a revolution in how physicians treat patients. This network will lead that revolution,” said Dr. Patrick Maxwell, Regius professor of physic and head of the School of Clinical Medicine, University of Cambridge.

"The understanding of the science that drives cancer growth is leading to rapid and significant changes in how we need to approach the diagnosis, monitoring and treatment of patients with cancer. If we are to be successful in bringing revolutionary new treatment regimens to patients quickly, it will require this kind of collaboration across cancer centers. AZ Oncology looks forward to also collaborating with Cancer Core Europe to help deliver this revolutionary vision,” said Susan Galbraith, head of oncology, AstraZeneca.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing